Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts

BACKGROUND: Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Macura, Sherrill L, Steinbacher, Jeremy L, MacPherson, Maximilian B, Lathrop, Melissa J, Sayan, Mutlay, Hillegass, Jedd M, Beuschel, Stacie L, Perkins, Timothy N, Spiess, Page C, van der Vliet, Albert, Butnor, Kelly J, Shukla, Arti, Wadsworth, Marilyn, Landry, Christopher C, Mossman, Brooke T
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2013
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3846908/
https://ncbi.nlm.nih.gov/pubmed/24024776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-400
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi